#1 Clinical Trials Search in Europe

Itolizumab

Itolizumab is an investigational drug currently being studied in clinical trials for its potential to treat various medical conditions. These trials aim to evaluate the safety, effectiveness, and optimal dosing of Itolizumab in patients with dermatomyositis, acute respiratory distress syndrome (ARDS), acute graft-versus-host disease (aGVHD), systemic lupus erythematosus, and COVID-19 complications. The drug shows promise in modulating the immune system and reducing inflammation, which could benefit patients with these challenging conditions.

Table of Contents

What is Itolizumab?

Itolizumab, also known by its alternative names T1h and Bmab600, is an investigational drug being studied for its potential to treat various autoimmune and inflammatory conditions[1][4]. It is a type of medication called a monoclonal antibody, which means it’s a laboratory-created protein designed to target specific cells in the body. Itolizumab is not yet approved for general use and is currently being evaluated in clinical trials to determine its safety and effectiveness.

Conditions Treated with Itolizumab

Researchers are exploring the use of Itolizumab in several different medical conditions, including:

  • Dermatomyositis: A rare autoimmune disease that causes skin rashes and muscle weakness[1]
  • Acute Respiratory Distress Syndrome (ARDS): A severe lung condition that causes difficulty breathing[2]
  • Acute Graft Versus Host Disease (aGVHD): A complication that can occur after a bone marrow or stem cell transplant[3]
  • Systemic Lupus Erythematosus (SLE): An autoimmune disease that can affect various parts of the body[4]
  • Lupus Nephritis: A kidney inflammation caused by SLE[4]
  • COVID-19 complications: Including cytokine release syndrome, a severe inflammatory response[5]

How Itolizumab Works

Itolizumab works by targeting a specific protein called CD6 on the surface of certain immune cells (T cells)[1][2]. By binding to CD6, Itolizumab may help to reduce inflammation and modulate the immune response. This mechanism of action is particularly important in autoimmune diseases, where the immune system mistakenly attacks the body’s own tissues.

The drug is being studied for its ability to affect various inflammatory markers in the body, such as:

  • Interleukins (IL-2, IL-6, IL-8, IL-17)
  • Tumor Necrosis Factor-alpha (TNF-α)
  • Interferon-gamma (IFN-γ)
  • C-reactive protein (CRP)
  • Ferritin

These markers are often elevated in inflammatory conditions, and reducing their levels may help improve symptoms and outcomes for patients[1][2][3].

How Itolizumab is Administered

Itolizumab is typically administered in one of two ways:

  1. Intravenous (IV) infusion: The medication is given directly into a vein. This method is being used in several trials, with doses ranging from 25 mg to 150 mg, usually given every two weeks[1][2][3].
  2. Subcutaneous injection: The medication is injected under the skin. This method is being tested in some trials, with doses calculated based on the patient’s weight (e.g., 0.4 – 3.2 mg/kg)[4].

The frequency and duration of treatment can vary depending on the condition being treated and the specific clinical trial protocol.

Current Clinical Trials

Itolizumab is currently being studied in several Phase 1 and Phase 2 clinical trials. These trials are designed to evaluate the drug’s safety, how it’s processed by the body (pharmacokinetics), its effects on the immune system (pharmacodynamics), and its potential effectiveness in treating various conditions. Some key trials include:

  • A study in patients with dermatomyositis[1]
  • A trial for acute respiratory distress syndrome caused by infectious pneumonia[2]
  • Research on newly diagnosed acute graft versus host disease[3]
  • A study in patients with systemic lupus erythematosus, with or without lupus nephritis[4]
  • An investigation into Itolizumab’s efficacy in COVID-19 complications[5]

Safety and Side Effects

As Itolizumab is still in the investigational stage, its full safety profile is not yet established. The ongoing clinical trials are carefully monitoring for any adverse effects. Common methods for assessing safety include:

  • Tracking the incidence of treatment-emergent adverse events
  • Monitoring vital signs and laboratory test results
  • Assessing the development of anti-drug antibodies (ADA)

It’s important to note that as an investigational drug, the benefits and risks of Itolizumab are still being evaluated. Patients considering participation in clinical trials should discuss the potential risks and benefits with their healthcare providers[1][2][3][4][5].

Condition Trial Phase Dosage Range Administration Key Outcomes Measured
Dermatomyositis Phase 1 25-100 mg IV infusion every 2 weeks, 7 doses Safety, PK/PD, inflammatory markers, clinical improvement
ARDS Phase 1 50-150 mg IV infusion, single dose with option to continue Safety, PK/PD, lung function, inflammatory markers
Acute GVHD Phase 1 25-150 mg IV infusion every 2 weeks, 5 doses Safety, PK/PD, response rate, steroid use reduction
Lupus Erythematosus Phase 1b 0.4-3.2 mg/kg Subcutaneous injection every 2 weeks, 2-13 doses Safety, PK/PD, CD6 receptor occupancy
COVID-19 Complications Phase 2 1.6 mg/kg IV infusion, flexible dosing up to 4 weeks Mortality rate, lung function, inflammatory markers

FAQ

  • What is Itolizumab? Itolizumab is an investigational drug that targets the CD6 receptor on T cells. It is being studied for its potential to modulate the immune system and reduce inflammation in various medical conditions.
  • What conditions is Itolizumab being tested for in clinical trials? Itolizumab is being tested in clinical trials for dermatomyositis, acute respiratory distress syndrome (ARDS), acute graft-versus-host disease (aGVHD), systemic lupus erythematosus, and COVID-19 complications.
  • How is Itolizumab administered in these trials? In most trials, Itolizumab is administered through intravenous (IV) infusion. The dosage and frequency vary depending on the specific trial and condition being studied, ranging from single doses to multiple doses given every two weeks.
  • What are the main goals of these clinical trials? The main goals of these trials are to evaluate the safety, tolerability, pharmacokinetics (how the drug moves through the body), pharmacodynamics (how the drug affects the body), and clinical effectiveness of Itolizumab in treating the targeted conditions.
  • Are there any known side effects of Itolizumab? As Itolizumab is still being studied, the full range of potential side effects is not yet known. The clinical trials are designed to monitor and assess any adverse events that may occur during treatment. Common methods for tracking side effects include using the Common Terminology Criteria for Adverse Events (CTCAE) and monitoring for the development of anti-drug antibodies.

Ongoing Clinical Trials on Itolizumab

  • Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

    Not recruiting

    3 1
    Investigated drugs:
    Belgium France Germany Italy Portugal Spain

Glossary

  • Itolizumab: An investigational drug that targets the CD6 receptor on T cells, being studied for its potential to modulate the immune system and reduce inflammation in various medical conditions.
  • Dermatomyositis: A rare inflammatory disease characterized by muscle weakness and skin rash.
  • Acute Respiratory Distress Syndrome (ARDS): A serious lung condition characterized by rapid onset of widespread inflammation in the lungs, leading to difficulty breathing.
  • Acute Graft-Versus-Host Disease (aGVHD): A complication that can occur after a bone marrow or stem cell transplant, where the donor's immune cells attack the recipient's tissues.
  • Systemic Lupus Erythematosus: A chronic autoimmune disease that can affect various parts of the body, including skin, joints, kidneys, brain, and other organs.
  • Cytokine Release Syndrome: A systemic inflammatory response that can occur as a side effect of certain immunotherapies or severe infections, characterized by high fever, inflammation, and organ dysfunction.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and biochemical and physiological effects.
  • Intravenous (IV) infusion: A method of administering medication directly into a vein using a needle or catheter.
  • Anti-drug antibodies (ADA): Antibodies produced by the immune system in response to a therapeutic drug, which can potentially reduce the drug's effectiveness or cause adverse reactions.

References

  1. https://clinicaltrials.gov/study/NCT05986162
  2. https://clinicaltrials.gov/study/NCT05978544
  3. https://clinicaltrials.gov/study/NCT05823675
  4. https://clinicaltrials.gov/study/NCT04128579
  5. https://clinicaltrials.gov/study/NCT04475588